It is a scarce resource, antibodies don't last forever and we have to capture people within that time window. This is dependant on the progression of COVID-19 within different geographies.

Julie Kim

When the product will be available beyond the clinical study is still a bit unclear, but we do expect that before the end of the year, we should see some information in terms of broader use.